SRL
TSHA icon

Scientech Research LLC’s Taysha Gene Therapies TSHA Stock Holding History

Scientech Research LLC’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,040
Closed -$94K – 541
2026
Q1 		$94K Buy
21,040
+2,864
+16% +$13.3K 0.08% 345
2025
Q4 		$100K Buy
+18,176
New +$88.3K 0.06% 409
2024
Q3 		– Sell
-43,350
Closed -$97.1K – 847
2024
Q2 		$97.1K Buy
+43,350
New +$126K 0.02% 546

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Scientech Research LLC's TSHA Position: Q2 2026 in Review

Scientech Research LLC sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 21,040 shares — an estimated $94K sold.

Scientech Research LLC first reported a position in TSHA in Q2 2024 and held it in 3 quarters. The position peaked at $100K in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Scientech Research LLC reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Scientech Research LLC sold 21,040 Taysha Gene Therapies shares in Q2 2026, an estimated $94K.
  • Scientech Research LLC first reported a position in Taysha Gene Therapies in Q2 2024 and held it in 3 quarters.
  • Scientech Research LLC's Taysha Gene Therapies position peaked at $100K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.